244 results on '"Giobbie-Hurder, Anita"'
Search Results
2. Supplementary table 2 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
3. Supplementary table 3 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
4. Data from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
5. FIGURE 2 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
6. Data from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
7. Supplementary table 1 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
8. Supplementary table 2 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
9. TABLE 2 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
10. TABLE 1 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
11. FIGURE 3 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
12. Supplementary table 3 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
13. FIGURE 1 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
14. TABLE 2 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
15. Supplementary table 1 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
16. TABLE 1 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
17. FIGURE 2 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
18. FIGURE 3 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
19. A Phase II study of ERK inhibition by ulixertinib (BVD-523) in Metastatic Uveal Melanoma
20. Supplementary Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
21. Supplementary Figure 3 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
22. Supplementary Figure 2 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
23. Supplementary Figure 5 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
24. Supplementary Figure legends from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
25. Supplementary Figure 4 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
26. Supplementary Figure 2 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
27. Supplementary Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
28. Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
29. Supplementary Figure 4 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
30. Supplementary Figure 1 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
31. Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
32. Supplementary Figure 5 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
33. Supplementary Figure legends from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
34. Supplementary Figure 3 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
35. Supplementary Figure 1 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
36. EDIL3 as an angiogenic target of immune exclusion following checkpoint blockade
37. Data from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
38. Supplementary Data 1 from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
39. Supplementary Data 1 from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
40. Data from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
41. Supplementary Figure 1 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
42. Supplementary Figure 1 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
43. Data from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
44. Supplementary Figure 3 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
45. Supplementary Figure 4 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
46. Supplementary Figure 3 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
47. Supplementary Figure 4 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
48. Supplementary Table 1 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
49. Supplementary Figure 6 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
50. Supplementary Figure 7 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.